Relation Between C-Reactive Protein, Homocysteine Levels, Fibrinogen, and Lipoprotein Levels and Leukocyte and Platelet Counts, and 10-Year Risk for Cardiovascular Disease Among Healthy Adults in the USA

American Journal of Cardiology

Volumn 105, Issue 9, 2010, Pages 1284-1288

  Park, Chan Seok ^a   Ihm, Sang Hyun ^a   Yoo, Ki Dong ^a   Kim, Dong Bin ^a   Lee, Jong Min ^a   Kim, Hee Yeol ^a   Chung, Wook Sung ^a   Seung, Ki Bae ^a   Kim, Jae Hyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; CALCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENDER; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; RACE; SCORING SYSTEM; THROMBOCYTE; THROMBOCYTE COUNT; UNITED STATES;

ADULT; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; INCIDENCE; LEUKOCYTE COUNT; LIPOPROTEINS; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 77950858918     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.045     Document Type: Article

References (23)

1. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
2. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
3. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., Hutchinson W.L., and Pepys M.B. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
5. Steenland K., Sieber K., Etzel R.A., Pechacek T., and Maurer K. Exposure to environmental tobacco smoke and risk factors for heart disease among never smokers in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 147 (1998) 932-939
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
7. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
8. Corrado E., and Novo S. Role of inflammation and infection in vascular disease. Acta Chir Belg 105 (2005) 567-579
9. Danesh J., Lewington S., Thompson S.G., Lowe G.D., Collins R., Kostis J.B., Wilson A.C., Folsom A.R., Wu K., Benderly M., Goldbourt U., Willeit J., Kiechl S., Yarnell J.W., Sweetnam P.M., Elwood P.C., Cushman M., Psaty B.M., Tracy R.P., Tybjaerg-Hansen A., Haverkate F., de Maat M.P., Fowkes F.G., Lee A.J., Smith F.B., Salomaa V., Harald K., Rasi R., Vahtera E., Jousilahti P., Pekkanen J., D'Agostino R., Kannel W.B., Wilson P.W., Tofler G., Arocha-Pinango C.L., Rodriguez-Larralde A., Nagy E., Mijares M., Espinosa R., Rodriquez-Roa E., Ryder E., Diez-Ewald M.P., Campos G., Fernandez V., Torres E., Marchioli R., Valagussa F., Rosengren A., Wilhelmsen L., Lappas G., Eriksson H., Cremer P., Nagel D., Curb J.D., Rodriguez B., Yano K., Salonen J.T., Nyyssonen K., Tuomainen T.P., Hedblad B., Lind P., Loewel H., Koenig W., Meade T.W., Cooper J.A., De Stavola B., Knottenbelt C., Miller G.J., Bauer K.A., Rosenberg R.D., Sato S., Kitamura A., Naito Y., Palosuo T., Ducimetiere P., Amouyel P., Arveiler D., Evans A.E., Ferrieres J., Juhan-Vague I., Bingham A., Schulte H., Assmann G., Cantin B., Lamarche B., Despres J.P., Dagenais G.R., Tunstall-Pedoe H., Woodward M., Ben-Shlomo Y., Davey Smith G., Palmieri V., Yeh J.L., Rudnicka A., Ridker P., Rodeghiero F., Tosetto A., Shepherd J., and Ford I. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1799-1809
10. Kannel W.B., Anderson K., and Wilson P.W. White blood cell count and cardiovascular disease. Insights from the Framingham study. JAMA 267 (1992) 1253-1256
11. Hoffman M., Blum A., Baruch R., Kaplan E., and Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis 172 (2004) 1-6
12. Koenig W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
13. Mora S., Rifai N., Buring J.E., and Ridker P.M. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 114 (2006) 381-387
14. van der Meer I.M., de Maat M.P., Kiliaan A.J., van der Kuip D.A., Hofman A., and Witteman J.C. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 163 (2003) 1323-1328
15. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
16. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
17. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., and Gotto Jr. A.M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
18. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E., and Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
19. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., and Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
20. Morrow D.A., de Lemos J.A., Sabatine M.S., Wiviott S.D., Blazing M.A., Shui A., Rifai N., Califf R.M., and Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114 (2006) 281-288
21. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
22. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., and Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
23. Taylor D.R. Risk assessment in asthma and COPD: a potential role for biomarkers?. Thorax 64 (2009) 261-264